1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Boehringer Doubles Down On Deafness With Rinri Backing

 
• By Kevin Grogan

After making a move into hearing loss with an investment into Acousia Therapeutics, BI is backing a UK biotech which hopes to reverse neuropathic sensorineural hearing loss.

Hearing_Loss
BI and UCB lead £1.4m round for hearing loss start-up Rinri • Source: Shutterstock

The UK's Rinri Therapeutics, a spin-out of Sheffield University, has bagged two major pharma players in Boehringer Ingelheim GmbH and UCB Group, to help fund development of its cell-based therapy to restore hearing.

Rinri has secured £1.4m in seed funding from the venture capital arms of BI and UCB and the health-centered business incubator BioCity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.